Success Metrics

Clinical Success Rate
100.0%

Based on 9 completed trials

Completion Rate
100%(9/9)
Active Trials
0(0%)
Results Posted
100%(9 trials)

Phase Distribution

Ph phase_3
8
89%
Ph phase_2
1
11%

Phase Distribution

0

Early Stage

1

Mid Stage

8

Late Stage

Phase Distribution9 total trials
Phase 2Efficacy & side effects
1(11.1%)
Phase 3Large-scale testing
8(88.9%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

9 of 9 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(9)

Detailed Status

Completed9

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 21 (11.1%)
Phase 38 (88.9%)

Trials by Status

completed9100%

Recent Activity

0 active trials
Showing 5 of 9
completedphase_3

A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults

NCT01715415
completedphase_3

A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Subjects With Chronic Hepatitis C

NCT01674725
completedphase_3

A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection

NCT01767116
completedphase_3

A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection

NCT01833533
completedphase_3

A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis

NCT01704755
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT01715415Phase 3

A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults

Completed
NCT01674725Phase 3

A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Subjects With Chronic Hepatitis C

Completed
NCT01767116Phase 3

A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection

Completed
NCT01833533Phase 3

A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection

Completed
NCT01704755Phase 3

A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis

Completed
NCT01716585Phase 3

A Study to Evaluate Chronic Hepatitis C Infection

Completed
NCT01995071Phase 2

A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)

Completed
NCT01854528Phase 3

A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults

Completed
NCT01854697Phase 3

A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9